Our present study firstly provided the evidence that JQJT tablets, a clinically commonly used Chinese patent medicine, could improve T2DM insulin resistance by regulating the gut microbiota, promoting the production of SCFAs, and the mechanism was related to increasing gut barrier function subsequently reducing the host inflammatory reaction. The gene discussed is INS; the disease is type 2 diabetes mellitus.